ID   C-HC-4
AC   CVCL_W519
SY   c-Hc-4; C-Hc4; cHc4; CHC4; HC-4; Hc-4
DR   CGH-DB; 9073-4
DR   ChEMBL-Cells; CHEMBL4523518
DR   ChEMBL-Targets; CHEMBL4523549
DR   PubChem_Cell_line; CVCL_W519
DR   TKG; TKG 0733
DR   Wikidata; Q54799760
RX   PubMed=2543326;
RX   PubMed=2856442;
RX   PubMed=6300668;
RX   PubMed=7874267;
RX   PubMed=12029633;
CC   Population: Japanese.
CC   Doubling time: ~20 hours (PubMed=2856442).
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): TKG=TKG 0733
ST   Amelogenin: X
ST   CSF1PO: 13
ST   D13S317: 11
ST   D16S539: 9
ST   D5S818: 10
ST   D7S820: 10,12
ST   TH01: 6,9
ST   TPOX: 9
ST   vWA: 14,18
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 02-05-24; Version: 13
//
RX   PubMed=2543326;
RA   Hata Y., Igarashi M., Takada N., Namieno T., Sasaki F., Une Y.,
RA   Uchino J., Kajiwara M.;
RT   "Development of a new therapeutic method in hepatocellular carcinoma
RT   using a culture system -- the intensifying effect of human epidermal
RT   growth factor (hEGF) on the antitumor action of antitumor agents.";
RL   Gan To Kagaku Ryoho 16:1874-1879(1989).
//
RX   PubMed=2856442;
RA   Sasaki F., Kameda H., Hata Y., Uchino J.;
RT   "Establishment of the human hepatocellular carcinoma cell line and its
RT   characteristics.";
RL   Hum. Cell 1:89-91(1988).
//
RX   PubMed=6300668; DOI=10.1016/0027-5107(83)90097-0;
RA   Abe S., Nemoto N., Sasaki M.;
RT   "Sister-chromatid exchange induction by indirect mutagens/carcinogens,
RT   aryl hydrocarbon hydroxylase activity and benzo[alpha]pyrene
RT   metabolism in cultured human hepatoma cells.";
RL   Mutat. Res. 109:83-90(1983).
//
RX   PubMed=7874267; DOI=10.1007/BF02349278;
RA   Ikuta S., Itoh F., Hinoda Y., Toyota M., Makiguchi Y., Imai K.,
RA   Yachi A.;
RT   "Expression of cytoskeletal-associated protein tyrosine phosphatase
RT   PTPH1 mRNA in human hepatocellular carcinoma.";
RL   J. Gastroenterol. 29:727-732(1994).
//
RX   PubMed=12029633; DOI=10.1053/jhep.2002.33683;
RA   Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M.,
RA   Inazawa J.;
RT   "TFDP1, CUL4A, and CDC16 identified as targets for amplification at
RT   13q34 in hepatocellular carcinomas.";
RL   Hepatology 35:1476-1484(2002).
//